You seem to be using an outdated version of Internet Explorer. Please note that this site does not support this browser version (a href="">as does Microsoft). You may experience design inconsistencies and error messages. We are sorry for any inconveniences.

Portfolio Finder

Current Startups


TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences.

Info & Contact

Dr. Matthias Schaier
+49 6221 5639930


TolerogenixX GmbH
Im Neuenheimer Feld 162
69120 Heidelberg

Added to portfolio

21. Dec 2016